Navigation Links
First all-African GM crop is resistant to maize streak virus
Date:8/15/2007

The first all-African genetically modified crop plant with resistance to the severe maize streak virus (MSV), which seriously reduces the continents maize yield, has been developed by scientists from the University of Cape Town and PANNAR PTY Ltd, a South African seed company. The research, published in Plant Biotechnology Journal represents a significant advance in African agricultural biotechnology, and will play an important role in alleviating Africas food shortages and famine.

Dr Dionne Shepherd, lead researcher explains, MSV is transmitted to maize by small insects called leafhoppers. The disease is therefore a result of a complex interplay between the plant, the virus and insect. Factors that can influence the severity of the disease include the age at which the plant is infected (the younger the plant, the more severe the infection), the maize variety (some are more susceptible than others), and environmental conditions.

We have created an MSV-resistant maize variety by genetic engineering, using an approach known as pathogen-derived resistance. This means that a gene from the viral pathogen is used to protect the plant from that pathogen. We mutated a viral gene that under normal circumstances produces a protein that is essential for the virus to replicate itself and inserted it into the maize plants genome, creating genetically modified maize. When the virus infects one of these transgenic maize plants, it displays a significant delay in symptom development, a decrease in symptom severity and higher survival rates than non-transgenic plants.

The next stage of the research involves field trials to ensure that the transformed crop is digestible, that the protein is not an allergen and that it will be ecologically friendly to other organisms within the environment. Following the results of these trials, the crop will be monitored over a number of growing seasons before it is made accessible to local farmers.


'/>"/>

Contact: Lucy Mansfield
lucy.mansfield@oxon.blackwellpublishing.com
44-186-547-6241
Blackwell Publishing Ltd.
Source:Eurekalert

Page: 1

Related biology news :

1. A genes first kiss sets off that affair known as puberty
2. Timing is everything: First step in protein building revealed
3. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
6. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Love at first smell
9. Worlds largest rainforest drying experiment completes first phase
10. PCRM develops worlds first cruelty-free insulin assay
11. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
Breaking Biology Technology: